scholarly article | Q13442814 |
P50 | author | James Douketis | Q100404477 |
Jerrold Levy | Q39056210 | ||
P2093 | author name string | Truman J Milling | |
Joshua N Goldstein | |||
Thorsten Steiner | |||
P2860 | cites work | Rapid large pulmonary embolism after prothrombin complex concentrate for warfarin reversal during colonoscopy | Q88235369 |
Efficacy and safety of a 4-factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgical or invasive procedures: a prospective, open-label, single-arm | Q88792311 | ||
European Stroke Organisation (ESO) Guidelines for the Management of Spontaneous Intracerebral Hemorrhage | Q57384692 | ||
Bleeding risk assessment and management in atrial fibrillation patients | Q57627129 | ||
Periprocedural warfarin reversal with prothrombin complex concentrate | Q57907745 | ||
Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists | Q59541570 | ||
Biochemical comparison of seven commercially available prothrombin complex concentrates | Q81762781 | ||
Prevalence and implications of preinjury warfarin use: an analysis of the National Trauma Databank | Q83223998 | ||
Prothrombin complex concentrate (Octaplex): a Portuguese experience in 1152 patients | Q83748359 | ||
Intracardiac Thrombosis after Emergent Prothrombin Complex Concentrate Administration for Warfarin Reversal | Q85648585 | ||
Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers | Q87842081 | ||
Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study | Q88128923 | ||
Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24632951 | ||
The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition | Q27339343 | ||
Guidelines on oral anticoagulation with warfarin - fourth edition | Q28240666 | ||
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects | Q28247385 | ||
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association | Q28262545 | ||
Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial | Q28265484 | ||
On the use of prothrombin complex concentrate in patients with coagulopathy requiring tooth extraction | Q33392998 | ||
Case series of four-factor prothrombin complex concentrate for warfarin reversal before heart transplantation | Q33422149 | ||
Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation | Q33434776 | ||
Thrombogenicity of prothrombin complex concentrates | Q33739978 | ||
Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry | Q34019616 | ||
Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q34252907 | ||
Emergency reversal of anticoagulation: from theory to real use of prothrombin complex concentrates. A retrospective Italian experience | Q34633407 | ||
Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial | Q35219638 | ||
Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q35752584 | ||
Comparison between Prothrombin Complex Concentrate (PCC) and Fresh Frozen Plasma (FFP) for the Urgent Reversal of Warfarin in Patients with Mechanical Heart Valves in a Tertiary Care Cardiac Center | Q35897909 | ||
Death and disability from warfarin-associated intracranial and extracranial hemorrhages | Q36501858 | ||
Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal | Q36584522 | ||
Prothrombin complex concentrate for warfarin-induced bleeding in a patient with a mechanical aortic valve. | Q37024233 | ||
Perioperative hemostatic management of patients treated with vitamin K antagonists | Q37306386 | ||
Real world usage of PCC to "rapidly" correct warfarin induced coagulopathy | Q37306733 | ||
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor | Q37655400 | ||
Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers | Q37701146 | ||
Novel oral anticoagulants: implications in the perioperative setting | Q37779223 | ||
Prothrombin complex concentrate for the urgent reversal of warfarin. Assessment of a standard dosing protocol | Q38002605 | ||
Rapid Warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. | Q38065635 | ||
Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate | Q38420791 | ||
Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. | Q38446560 | ||
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial | Q38469560 | ||
Novel oral anticoagulants and reversal agents: Considerations for clinical development | Q38509194 | ||
The Real-World Treatment of Hemorrhages Associated With Dabigatran and Rivaroxaban: A Multicenter Evaluation | Q38535227 | ||
Prothrombin complex concentrate for rapid reversal of warfarin anticoagulation to allow neuraxial blockade. | Q38561604 | ||
A new kid on the block: Outcomes with Kcentra 1 year after approval | Q38613007 | ||
Major bleeding, transfusions, and anemia: the deadly triad of cardiac surgery. | Q48956680 | ||
Low-dose 3-factor prothrombin complex concentrate for warfarin reversal prior to heart transplant | Q49062932 | ||
Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. | Q49155525 | ||
Reversal agents for non-vitamin K antagonist oral anticoagulants | Q49970899 | ||
2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways | Q50084592 | ||
A Retrospective Propensity Score-Matched Early Thromboembolic Event Analysis of Prothrombin Complex Concentrate vs Fresh Frozen Plasma for Warfarin Reversal Prior to Emergency Neurosurgical Procedures | Q50140400 | ||
Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. | Q50225548 | ||
Questionable reversal of anticoagulation in the therapeutic management of cerebral haemorrhage associated with vitamin K antagonists. | Q50773882 | ||
Use of Prothrombin Complex Concentrate for Warfarin Reversal Before the Performance of an Epidural Blood Patch in a Patient With Cortical Vein Thrombosis and Subdural Hematoma: A Case Report. | Q51319610 | ||
An international, multicenter, prospective study of a prothrombin complex concentrate, Prothromplex Total®, in anticoagulant reversal. | Q53077578 | ||
The benefit of prothrombin complex concentrate in decreasing neurological deterioration in patients with warfarin-associated intracerebral haemorrhage. | Q53081949 | ||
Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate. | Q53090736 | ||
Prothrombin complex concentrate facilitates emergency spinal surgery in anticoagulated patients. | Q53094595 | ||
Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study | Q53167882 | ||
Toward rational fresh frozen plasma transfusion: The effect of plasma transfusion on coagulation test results. | Q53254548 | ||
3-Factor Versus 4-Factor Prothrombin Complex Concentrate for Warfarin Reversal in Severe Bleeding: A Multicenter, Retrospective, Propensity-Matched Pilot Study. | Q53343255 | ||
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. | Q38682353 | ||
Management of Periprocedural and Early Pericardial Effusions With Tamponade Following Ablation of Atrial Fibrillation With Uninterrupted Factor Xa Inhibitors: A Case Series | Q38693172 | ||
When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. | Q38748850 | ||
Emergent reversal of vitamin K antagonists: addressing all the factors | Q38798692 | ||
Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal | Q38911940 | ||
Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association | Q38975409 | ||
Reversal of rivaroxaban anticoagulation by nonactivated prothrombin complex concentrate in urgent surgery | Q38993962 | ||
Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: First update 2016. | Q39275339 | ||
Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial | Q39683385 | ||
Retrospective study of rFVIIa, 4-factor PCC, and a rFVIIa and 3-factor PCC combination in improving bleeding outcomes in the warfarin and non-warfarin patient | Q39853866 | ||
Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants | Q40081589 | ||
Thromboembolic outcomes after use of a four-factor prothrombin complex concentrate for vitamin K antagonist reversal in a real-world setting. | Q40295049 | ||
Assessing the Efficacy of Prothrombin Complex Concentrate in Multiply Injured Patients With High-Energy Pelvic and Extremity Fractures. | Q40462219 | ||
Evaluation of Warfarin Reversal with 4-Factor Prothrombin Complex Concentrate Compared to 3-Factor Prothrombin Complex Concentrate at a Tertiary Academic Medical Center. | Q40470749 | ||
The effect of preinjury warfarin use on mortality rates in trauma patients: a European multicentre study | Q41471994 | ||
Comparative effectiveness of 3- versus 4-factor prothrombin complex concentrate for emergent warfarin reversal | Q41522803 | ||
Emergency neurosurgical care in patients treated with apixaban: report of 2 cases | Q41603394 | ||
Use of four-factor prothrombin complex concentrate for the mitigation of rivaroxaban-induced bleeding in an emergent coronary artery bypass graft | Q42209654 | ||
Treatment of warfarin-related intracranial hemorrhage: a comparison of prothrombin complex concentrate and recombinant activated factor VII. | Q42742774 | ||
Reversal of warfarin associated coagulopathy with 4-factor prothrombin complex concentrate in traumatic brain injury and intracranial hemorrhage | Q43051467 | ||
Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects | Q43102398 | ||
Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: a prospective clinical trial of emergency anticoagulation reversal | Q43269909 | ||
Hospitalization for vitamin-K-antagonist-related bleeding: treatment patterns and outcome | Q43650765 | ||
An exploratory cohort study comparing prothrombin complex concentrate and fresh frozen plasma for the treatment of coagulopathy after complex cardiac surgery. | Q43802447 | ||
The effectiveness and safety of fixed low-dose prothrombin complex concentrates in patients requiring urgent reversal of warfarin | Q44241618 | ||
Efficacy of the prothrombin complex concentrate prothromplex in patients requiring urgent reversal of vitamin K antagonists or presenting with uncontrolled bleeding: a retrospective, single center study | Q44313606 | ||
Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy | Q44779656 | ||
The use of prothrombin complex concentrates in two patients with non-pulsatile left ventricular assist devices | Q44920280 | ||
The exclusive use of coagulation factor concentrates enables reversal of coagulopathy and decreases transfusion rates in patients with major blunt trauma | Q45343282 | ||
Prothrombin complex concentrate accelerates international normalized ratio reversal and diminishes the extension of intracranial hemorrhage in geriatric trauma patients | Q45896567 | ||
Four-Factor Prothrombin Complex Concentrate Reduces Time to Procedure in Vitamin K Antagonist-Treated Patients Experiencing Gastrointestinal Bleeding: A Post Hoc Analysis of Two Randomized Controlled Trials. | Q46516369 | ||
Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation | Q46918805 | ||
Emergency reversal of anticoagulation: the real use of prothrombin complex concentrates: a prospective multicenter two year French study from 2006 to 2008. | Q46959051 | ||
Effectiveness of Factor IX complex concentrate in reversing warfarin associated coagulopathy for intracerebral hemorrhage | Q46979280 | ||
Intraoperative Administration of 4-Factor Prothrombin Complex Concentrate Reduces Blood Requirements in Cardiac Transplantation | Q47202088 | ||
Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. | Q47914091 | ||
Use of low-dose prothrombin complex concentrate before lumbar puncture | Q48132997 | ||
Reversal of anticoagulation with four-factor prothrombin complex concentrate without concurrent vitamin K (phytonadione) for urgent surgery in a patient at moderate-to-high risk for thromboembolism. | Q48268883 | ||
The James Blundell Award Lecture 2006: transfusion and the treatment of haemorrhage: past, present and future | Q48327704 | ||
Rapid Anticoagulation Reversal With Prothrombin Complex Concentrate Before Emergency Brain Tumor Surgery | Q48614868 | ||
Prothrombin Complex Concentrates: An Alternative to Fresh Frozen Plasma | Q48651621 | ||
Treatment With Prothrombin Complex Concentrate to Enable Emergency Lumbar Puncture in Patients Receiving Vitamin K Antagonists | Q48826698 | ||
Is there a difference in efficacy, safety, and cost-effectiveness between 3-factor and 4-factor prothrombin complex concentrates among trauma patients on oral anticoagulants? | Q48837088 | ||
Prothrombin complex concentrate versus fresh-frozen plasma for reversal of coagulopathy of trauma: is there a difference? | Q48866953 | ||
Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage. | Q48876772 | ||
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | vitamin | Q34956 |
vitamin K | Q182338 | ||
(E)-phytonadione | Q186093 | ||
anticoagulant | Q215118 | ||
anticoagulation | Q63279445 | ||
P1104 | number of pages | 14 | |
P304 | page(s) | 1171-1184 | |
P577 | publication date | 2018-12-01 | |
P1433 | published in | Anesthesiology | Q2012635 |
P1476 | title | Prothrombin Complex Concentrates for Perioperative Vitamin K Antagonist and Non-vitamin K Anticoagulant Reversal | |
P478 | volume | 129 |
Q90368700 | Catastrophic Intracardiac Thrombosis During Emergency Repair of an Expanding Aortic Pseudoaneurysm: A Case Report |
Q89458478 | Management of two major postoperative bleeding complications after mandible reconstruction with fibula free flap in a patient under chronic warfarin treatment |
Q99203763 | Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease |
Search more.